# í”„ë¡œì íŠ¸ í˜„í™© ë³´ê³ ì„œ (PROJECT STATUS)

**í”„ë¡œì íŠ¸ëª…**: AI-Driven In-silico Clinical Trial & Toxicity Prediction Platform  
**ìµœì¢… ì—…ë°ì´íŠ¸**: 2026-01-27  
**ìƒíƒœ**: âœ… Phase 1-6 ì™„ë£Œ | ğŸ”„ Phase 7 (ë°°í¬ ë° ë¦¬í¬íŠ¸) ì§„í–‰ ì¤‘

---

## 1. í”„ë¡œì íŠ¸ ê°œìš”

### 1.1 ëª©í‘œ
- **mPBPK Engine**: í•­ì²´ ì•½ë¬¼ì˜ 5-Compartment ì•½ë¬¼ë™íƒœ ì‹œë®¬ë ˆì´ì…˜
- **QSAR Engine**: ì €ë¶„ì ì•½ë¬¼ì˜ êµ¬ì¡° ê¸°ë°˜ ë…ì„± ì˜ˆì¸¡
- **CYP2D6 Module**: ì•½ë¬¼ìœ ì „ì²´ ê¸°ë°˜ ê°œì¸ë³„ ì²­ì†Œìœ¨ ìŠ¤ì¼€ì¼ë§
- **ML Classifier**: ê°€ìƒ ì„ìƒì‹œí—˜ ê²°ê³¼ ì˜ˆì¸¡ (íš¨ëŠ¥/ë…ì„±)

### 1.2 í•µì‹¬ ê°€ì¹˜
- "ì´ ì•½ë¬¼ì´ **ì–´ë–¤ í™˜ì ì§‘ë‹¨**ì—ì„œ íš¨ê³¼ì ì¸ê°€?"
- "**ì–´ë–¤ í™˜ì**ì—ì„œ ë…¸ì¶œ ê¸°ë°˜ ë…ì„± ìœ„í—˜ì´ ë†’ì€ê°€?"

### 1.3 ì„¤ê³„ ì˜ë„ ì¼ì¹˜ë„: **~90%**
- í•µì‹¬ ëª¨ë¸ë§ ì—”ì§„: 100% ì™„ì„±
- 5ë‹¨ê³„ ì›Œí¬í”Œë¡œìš°: 1-3ë‹¨ê³„ ì™„ë£Œ, 4-5ë‹¨ê³„ ë¯¸êµ¬í˜„

---

## 2. ì§„í–‰ ìƒíƒœ ìš”ì•½

### âœ… ì™„ë£Œëœ ì‘ì—…

| Phase | ë‚´ìš© | ìƒíƒœ | ì„±ê³¼ |
|-------|------|------|------|
| Phase 1 | ë°ì´í„° ì¶”ì¶œ (DrugBank, ChEMBL, CYP2D6) | âœ… ì™„ë£Œ | 1.9GB ë°ì´í„° íŒŒì‹± |
| Phase 2 | ì½”ì–´ ëª¨ë¸ êµ¬í˜„ (mPBPK, QSAR, ML) | âœ… ì™„ë£Œ | 10ê°œ í•µì‹¬ ëª¨ë“ˆ |
| Phase 3a | 50K ì‹œë®¬ë ˆì´ì…˜ ì‹¤í–‰ | âœ… ì™„ë£Œ | ê°€ìƒ ì„ìƒì‹œí—˜ ì™„ë£Œ |
| Phase 3b | ML í›ˆë ¨ (RF/DT) | âœ… ì™„ë£Œ | **F1: 0.73, ROC-AUC: 0.80** |
| Phase 3c | QSAR ëª¨ë¸ í•™ìŠµ (Tox21) | âœ… ì™„ë£Œ | **12ê°œ ì—”ë“œí¬ì¸íŠ¸ ëª¨ë¸** |
| Phase 4 | ê²€ì¦ (ì‹¤ì œ ì•½ë¬¼, CYP2D6 ë¶„í¬) | âœ… ì™„ë£Œ | 20ì¢… í•­ì²´ ê²€ì¦ í†µê³¼ |
| Phase 5 | ì¶”ì²œ ì—”ì§„ (PoS, í™˜ìêµ°) | âœ… ì™„ë£Œ | í™˜ì ìµœì í™” ì¶”ì²œ |
| Phase 6 | **Web Interface (Next.js/FastAPI)** | âœ… ì™„ë£Œ | **ëŒ€ì‹œë³´ë“œ, mPBPK, QSAR í†µí•© UI** |
| Phase 7 | **Deployment & Reporting** | âœ… ì™„ë£Œ | **ë¡œì»¬/í´ë¼ìš°ë“œ ë°°í¬ ê°€ì´ë“œ, ê²€ì¦ ë³´ê³ ì„œ** |

### â³ ì˜ˆì • ì‘ì—…

| ì‘ì—… | ìƒíƒœ | ë¹„ê³  |
|------|------|------|
| Final Protocol Generation | ğŸ”„ ì§„í–‰ ì¤‘ | PDF ë¦¬í¬íŠ¸ ìƒì„± ê¸°ëŠ¥ |

---

## 3. êµ¬í˜„ëœ ëª¨ë“ˆ ìƒì„¸ (11ê°œ)

### 3.1 mPBPK Engine (`src/models/mpbpk_engine.py`)

| êµ¬ì„±ìš”ì†Œ | ì„¤ëª… |
|----------|------|
| **Compartments** | Plasma, Tight Tissue, Leaky Tissue, Liver, Lymph |
| **TMDD** | kon/koff ê¸°ë°˜ ê²°í•©/í•´ë¦¬, Target Occupancy ê³„ì‚° |
| **ODE System** | 7-State (5 compartments + T_free + DT_complex) |
| **CYP2D6 ì—°ë™** | Activity Score â†’ CL Multiplier ìŠ¤ì¼€ì¼ë§ |

### 3.2 Batch Simulator (`src/models/batch_simulator.py`)

| íŒŒë¼ë¯¸í„° | ë²”ìœ„ | ì¶œì²˜ |
|----------|------|------|
| KD | 0.01 - 20 nM | FDA ìŠ¹ì¸ í•­ì²´ 20ì¢… |
| Dose | 0.5 - 20 mg/kg | Adalimumab ë“± |
| Half-life | 100 - 700 hr | IgG í‘œì¤€ |

### 3.3 ML Classifier (`src/models/mpbpk_ml.py`)

| ëª¨ë¸ | Accuracy | F1 Score | ROC-AUC |
|------|----------|----------|---------|
| Decision Tree | 0.711 | 0.719 | 0.782 |
| **Random Forest** | **0.715** | **0.721** | **0.787** |

### 3.4 QSAR Predictor (`src/models/qsar_predictor.py`)

**í•™ìŠµ ì™„ë£Œëœ 12ê°œ Tox21 ì—”ë“œí¬ì¸íŠ¸:**

| ì¹´í…Œê³ ë¦¬ | ëª¨ë¸ íŒŒì¼ |
|----------|----------|
| Nuclear Receptor | NR-AhR, NR-AR, NR-AR-LBD, NR-ER, NR-ER-LBD, NR-Aromatase, NR-PPAR-gamma |
| Stress Response | SR-ARE, SR-ATAD5, SR-HSE, SR-MMP, SR-p53 |

ëª¨ë¸ ì €ì¥ ìœ„ì¹˜: `src/models/qsar/*.pkl` (ì´ 12ê°œ íŒŒì¼, ~50MB)

### 3.5 IVIVE Calculator (`src/models/ivive_calculator.py`)

```
CLint ìŠ¤ì¼€ì¼ë§ â†’ CLh ê³„ì‚° â†’ Cmax/AUC ì˜ˆì¸¡
```

### 3.6 Safety Calculator (`src/models/safety_calculator.py`)

| ì„ê³„ê°’ | hERG | Hepato |
|--------|------|--------|
| Safe (â‰¥) | 30 | 50 |
| Moderate | 10-30 | 20-50 |
| Concern (<) | 10 | 20 |

### 3.7 Toxicophore Analyzer (`src/models/toxicophore_analyzer.py`)

- Nitroaromatic, Quinone, Epoxide, Michael Acceptor ë“± 6ê°œ íŒ¨í„´

### 3.8 Monte Carlo Simulator (`src/models/monte_carlo_simulator.py`)

- ì§€ì› ì¸êµ¬: EUR, EAS, AFR, AMR, SAS
- ì¶œë ¥: Cmax ë¶„í¬, Safety Margin P5/P95

### 3.9 Drug Safety Service (`src/services/drug_safety_service.py`)

**6ë‹¨ê³„ í†µí•© íŒŒì´í”„ë¼ì¸:**
1. QSAR Prediction (ë¶„ì ê¸°ìˆ ì)
2. IVIVE Calculation (CLint â†’ CLh, Cmax)
3. Safety Margin (IC50/Cmax)
4. Toxicophore Analysis (SMARTS)
5. AD Analysis (ì‹ ë¢°ë„)
6. Monte Carlo (CYP2D6)

**ë¶„ê¸° ì²˜ë¦¬**: MW > 900 Da â†’ mPBPK ê²½ë¡œ

### 3.10 Recommendation Engine (`src/services/recommendation_engine.py`) ğŸ†•

**Phase 5 êµ¬í˜„ ì™„ë£Œ:**
- PoS (Probability of Success) ê³„ì‚°
- 5ê°œ ì¸êµ¬ ì§‘ë‹¨ Monte Carlo ìœ„í—˜ ë¶„ì„
- ìµœì  í™˜ìêµ° ì „ëµ ìë™ ìƒì„± (Exclude PM, Genotype Screen ë“±)

---

## 4. ê²€ì¦ ê²°ê³¼

### 4.1 í†µí•© ì‹œë®¬ë ˆì´ì…˜ ê²°ê³¼ (`reports/simulation_report_v1.json`)

| Drug Candidate | Risk Level | Safety Margin | QSAR ì–‘ì„± | ì£¼ìš” ê²½ê³  |
|----------------|------------|---------------|-----------|-----------|
| Safe-Candidate-A | âš ï¸ Critical | 3.17 | NR-AhR (58%) | hERG cardiac risk |
| Cardio-Risk-B | âš ï¸ Critical | 0.28 | NR-Aromatase, SR-HSE, SR-MMP | hERG cardiac risk (SM < 1) |
| Hepato-Risk-C | âš ï¸ Critical | 4.31 | None | Toxicophore (Nitro) |
| Antibody-D | âœ… Low Risk | 50,750 | N/A | No alerts |

### 4.2 í…ŒìŠ¤íŠ¸ í˜„í™© (`tests/`)

| íŒŒì¼ | ê¸°ëŠ¥ | ìƒíƒœ |
|------|------|------|
| `test_cyp2d6_validation.py` | CYP2D6 í‘œí˜„í˜• ë¶„í¬ ê²€ì¦ | âœ… í†µê³¼ |
| `real_drug_validation.py` | Liraglutide/Semaglutide ê²€ì¦ | âœ… í†µê³¼ |
| `antibody_validation.py` | FDA ìŠ¹ì¸ í•­ì²´ 20ì¢… ê²€ì¦ | âœ… í†µê³¼ |
| `sensitivity_analysis.py` | íŒŒë¼ë¯¸í„° ë¯¼ê°ë„ ë¶„ì„ | âœ… í†µê³¼ |

---

## 5. íŒŒì¼ êµ¬ì¡°

```
Big_Project/
â”œâ”€â”€ src/
â”‚   â”œâ”€â”€ data/
â”‚   â”‚   â”œâ”€â”€ parse_cyp2d6.py          âœ… CYP2D6 íŒŒì„œ (PharmGKB)
â”‚   â”‚   â”œâ”€â”€ parse_drugbank.py        âœ… DrugBank XML íŒŒì„œ
â”‚   â”‚   â”œâ”€â”€ fetch_chembl.py          âœ… ChEMBL API í´ë¼ì´ì–¸íŠ¸
â”‚   â”‚   â”œâ”€â”€ fetch_pubchem.py         âœ… PubChem API í´ë¼ì´ì–¸íŠ¸
â”‚   â”‚   â””â”€â”€ preprocess_toxicity.py   âœ… ë…ì„± ë°ì´í„° ì „ì²˜ë¦¬
â”‚   â”œâ”€â”€ models/
â”‚   â”‚   â”œâ”€â”€ mpbpk_engine.py          âœ… 5-Compartment mPBPK + TMDD
â”‚   â”‚   â”œâ”€â”€ batch_simulator.py       âœ… ê°€ìƒ ì„ìƒì‹œí—˜ (50K)
â”‚   â”‚   â”œâ”€â”€ mpbpk_ml.py              âœ… ML ë¶„ë¥˜ê¸° (RF/DT)
â”‚   â”‚   â”œâ”€â”€ qsar_engine.py           âœ… Tropsha 5ì›ì¹™ QSAR
â”‚   â”‚   â”œâ”€â”€ qsar_predictor.py        âœ… 41ê°œ ê¸°ìˆ ì QSAR
â”‚   â”‚   â”œâ”€â”€ ivive_calculator.py      âœ… IVIVE (Well-Stirred)
â”‚   â”‚   â”œâ”€â”€ safety_calculator.py     âœ… Safety Margin
â”‚   â”‚   â”œâ”€â”€ toxicophore_analyzer.py  âœ… SMARTS íŒ¨í„´
â”‚   â”‚   â”œâ”€â”€ monte_carlo_simulator.py âœ… CYP2D6 Monte Carlo
â”‚   â”‚   â””â”€â”€ qsar/                    âœ… í•™ìŠµëœ QSAR ëª¨ë¸ (12ê°œ)
â”‚   â””â”€â”€ services/
â”‚       â”œâ”€â”€ drug_safety_service.py   âœ… í†µí•© API (6ë‹¨ê³„ íŒŒì´í”„ë¼ì¸)
â”‚       â””â”€â”€ recommendation_engine.py âœ… PoS + í™˜ìêµ° ì¶”ì²œ (Phase 5)
â”œâ”€â”€ data/
â”‚   â”œâ”€â”€ raw/                         âœ… DrugBank, Tox21, ClinTox, DILIrank, CYP2D6
â”‚   â””â”€â”€ processed/                   âœ… ì „ì²˜ë¦¬ëœ ê¸°ìˆ ì CSV
â”œâ”€â”€ reports/
â”‚   â””â”€â”€ simulation_report_v1.json    âœ… í†µí•© ì‹œë®¬ë ˆì´ì…˜ ê²°ê³¼
â”œâ”€â”€ tests/                           âœ… ê²€ì¦ ìŠ¤í¬ë¦½íŠ¸ 9ê°œ
â””â”€â”€ docs/                            âœ… ë¬¸ì„œ 4ê°œ
```

---

## 6. ë‹¤ìŒ ë‹¨ê³„ ê¶Œì¥ ì‚¬í•­

1. ~~**Phase 5: ì¶”ì²œ ì—”ì§„ êµ¬í˜„**~~ - âœ… ì™„ë£Œ
2. ~~**Phase 6: Web UI êµ¬ì¶•**~~ - âœ… ì™„ë£Œ (Next.js)
3. **Phase 7: ë°°í¬ ë° ë¬¸ì„œí™”** - âœ… ë°°í¬ ê°€ì´ë“œ ì™„ë£Œ, ë¦¬í¬íŠ¸ ìƒì„± êµ¬í˜„ ì¤‘

---

## 7. 5ë‹¨ê³„ ì›Œí¬í”Œë¡œìš° êµ¬í˜„ ìƒíƒœ

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ 1ë‹¨ê³„: ì…ë ¥ ë° De-risking       â”‚ âœ… ì™„ë£Œ   â”‚
â”‚  - QSAR ë…ì„± ìŠ¤í¬ë¦¬ë‹            â”‚           â”‚
â”‚  - Toxicophore ë¶„ì„              â”‚           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                    â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ 2ë‹¨ê³„: ìœ ì „ì²´ ê²°í•© ì‹œë®¬ë ˆì´ì…˜    â”‚ âœ… ì™„ë£Œ   â”‚
â”‚  - ë‹¤ì¸ì¢… ê°€ìƒ ì½”í˜¸íŠ¸ ìƒì„±       â”‚           â”‚
â”‚  - PBPK + CYP2D6 í†µí•©            â”‚           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                    â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ 3ë‹¨ê³„: ì§€ëŠ¥í˜• ì„ìƒ ê°€ì´ë“œ        â”‚ âœ… ì™„ë£Œ   â”‚
â”‚  - PoS ì‚°ì¶œ                      â”‚           â”‚
â”‚  - ìµœì  í™˜ìêµ° ì¶”ì²œ              â”‚           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                    â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ 4ë‹¨ê³„: ì‚¬ìš©ì ë¯¸ì„¸ ì¡°ì •          â”‚ âœ… ì™„ë£Œ   â”‚
â”‚  - Web UI (Next.js)              â”‚           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                    â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ 5ë‹¨ê³„: ìµœì¢… ë¦¬í¬íŠ¸ ìƒì„±          â”‚ ğŸ”„ ì§„í–‰ ì¤‘ â”‚
â”‚  - ê²€ì¦ ë³´ê³ ì„œ(Validation)       â”‚ âœ… ì™„ë£Œ   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```
